![]({"xs":"https:\/\/www.kepler-consulting.com\/wp-content\/uploads\/2023\/12\/chatgpt-image-20-juin-2026-12-29-44-640x0-c-default.png","md":"https:\/\/www.kepler-consulting.com\/wp-content\/uploads\/2023\/12\/chatgpt-image-20-juin-2026-12-29-44-1600x0-c-default.png"})
Cosmetics: Mastering the Product Lifecycle
Cosmetics remains a growth market, but that growth is becoming harder to convert into sustainable performance.
KEPLER intervenes to accelerate without disorganizing, simplify without weakening the offer, and secure growth without making the model rigid.
KEPLER intervenes to accelerate without disorganizing, simplify without weakening the offer, and secure growth without making the model rigid.
Turning your challenges into measurable results
- Speed remains a competitive advantage, but it only creates value if it leads to launches that are industrializable, compliant and profitable. Ingredient trends, expert routines, naturality and the pressure for novelty push brands to accelerate, while formulation, validation, claims, quality and industrialization continue to slow execution.
- The tension is even stronger when facing market models able to make innovation fast, clear and desirable. The challenge is therefore not simply to “go faster”, but to go faster without creating more rework, more documentation fragility and more friction between functions.
- Targeted diagnosis: end-to-end review of the development cycle, from insight to launch, to identify the real sources of delay, iteration and misalignment.
- Prioritized strategy: clarification of innovation priorities, expected levels of proof and projects to accelerate according to their business potential and industrial feasibility.
- Operational deployment: redesign of decision gates, reduction of validation loops, earlier securing of quality, claims, sourcing and industrialization constraints.
Measured results: reduced time-to-market, fewer iterations and stronger launch robustness.
When Brands Must Accelerate Innovation Without Weakening Market Launch
- Consumers want products that prove what they promise. “Clean”, “natural”, “eco”, “biodegradable” or “responsible” claims are increasingly monitored, and substantiation requirements are becoming stricter. At the same time, markets continue to reward brands that make innovation visible, easy to understand and quickly desirable.
- The tension is clear: more speed and more desirability, but also more proof, more rigor and less ambiguity around claims. This is now a competitiveness issue as much as a regulatory one.
- Targeted diagnosis: analysis of claim robustness and consistency between product benefit, formulation, proof and price.
- Prioritized strategy: prioritization of promises, expected proof levels by category and clarification of the value equation.
- Operational deployment: earlier integration of regulatory, quality and proof requirements into innovation projects, to secure market launch without slowing down speed.
Measured results: stronger claims, improved perceived value and reduced friction between marketing, R&D and regulatory teams.
When Claims Are More Scrutinized While the Market Rewards Fast Innovation
- The beauty market is increasingly disrupted by players able to quickly convert a social signal, trend or viral use case into a launch, activation and volume. Their advantage is not only based on marketing: it also comes from tighter assortments, shorter decision chains and greater production flexibility through external partners.
- For established brands, the issue is therefore not only digital or influencer-driven. It is structural: how to reduce the distance between market signal, decision, development, volume allocation and commercial execution. As long as this cycle remains too long, the brand reacts to the market instead of shaping it.
- Targeted diagnosis: measurement of the real speed of the growth model: decision lead times, portfolio inertia, supply rigidity and partner flexibility.
- Prioritized strategy: definition of a more agile operating model according to segments, categories and innovation rhythms.
- Operational deployment: portfolio simplification, reprioritization of hero products, clarified role of industrial partners and faster volume adjustment mechanisms.
Measured results: faster execution, better-adjusted volumes and improved market responsiveness.
When Established Brands Must Regain Speed Against Much More Agile Models
- The proliferation of references, formats, limited editions, variants and incremental innovations blurs portfolio readability and spreads costs across the entire value chain: procurement, packaging, quality, regulatory, planning, production and service.
- The challenge is not to cut “at scale”. It is to distinguish what truly creates growth, market presence or desirability from what consumes resources without sufficient return. This is simultaneously a portfolio, industrial and commercial arbitration.
- Targeted diagnosis: measurement of real value by SKU, range, format, channel and market.
- Prioritized strategy: definition of a target portfolio balancing growth, visibility and economic discipline.
- Operational deployment: selective rationalization, launch / delisting rules, design-to-value and stronger portfolio governance.
Measured results: improved margins, reduced complexity costs and a clearer portfolio.
When Brands Must Regain Control Over Portfolio Complexity
- Access to the right ingredients, pressure on certain assets, the rise of biotech, availability of packaging components and dependence on agile CDMO or OEM partners are making the value chain more sensitive. The fastest models are often also those that rely most heavily on external partners.
- This is compounded by a now central constraint: geopolitical exposure. The concentration of certain materials or capacities in China, tariff volatility, trade tensions and logistics fragility are bringing supplier risk management, dual sourcing and the development of partners able to raise their standards on compliance, innovation and flexibility back to the forefront. This applies both to ingredient manufacturers and CDMOs.
- The issue is therefore no longer only supply continuity. It is about deciding where to preserve flexibility, where to secure, where to duplicate, and where to internalize or protect strategic capabilities. It is a matter of strategic control as much as supply.
- Targeted diagnosis: mapping of critical ingredients, implementation of core formulas, supplier dependencies, packaging exposure, CDMO structure and quality / cost / lead-time vulnerabilities, with explicit integration of geopolitical risks, country dependencies, concentration points and disruption scenarios.
- Prioritized strategy: securing policy for critical ingredients, capacities and partners; make-or-buy / CDMO / dual sourcing arbitration; prioritization of supply chains to develop and partners to strengthen.
- Operational deployment: resilience plans, stronger partner management, volume / lead-time / quality adjustment mechanisms, supplier development and CDMO capability building on regulatory, innovation and execution flexibility topics.
Measured results: fewer disruptions, greater flexibility, stronger industrial resilience and reduced exposure to critical dependencies.
When Ingredients, Packaging, CDMO and Industrial Partners Become Critical Assets
- Regulatory tightening is no longer just a “back-office” constraint. It now directly affects development, packaging, proof, governance and market launch. In Europe, PPWR imposes a much more demanding logic on design, recyclability, material reduction and producer responsibility; CSRD strengthens reporting and organizational requirements around sustainability; EPR mechanisms are gaining momentum. In China, CSAR continues to raise expectations on ingredients, safety, labels, evaluations and registration discipline.
- The risk for brands is to treat these topics separately. Yet the stronger the requirements become, the more performance depends on the ability to integrate packaging, claims, data, reporting and market compliance upstream into product decisions.
- Targeted diagnosis: assessment of packaging, claims, traceability, reporting, documentation and compliance governance maturity.
- Prioritized strategy: integrated roadmap combining PPWR, EPR, CSRD, CSAR, claims and product data.
- Operational deployment: earlier integration of regulatory and documentation constraints into development and go-to-market cycles, reorganization of approval laboratories, process optimization and implementation of partnerships.
Measured results: reduced validation lead times, lower regulatory risk and stronger ability to absorb regulatory tightening without slowing growth.
When Regulatory Tightening Moves to the Core of the Model
- In cosmetics, AI only creates value if it shortens the time between a market signal and a useful decision. Producing more content, more monitoring or more reporting is not enough. What matters is the ability to accelerate trend reading, innovation qualification, dossier preparation, volume adjustment and synchronization between functions.
- The most structuring use cases sit in five areas:
- Early detection of trends and weak signals to prioritize innovation and distinguish short-lived hype from real potential.
- Support for formulation and the search for ingredient / packaging alternatives to reduce technical iterations, accelerate substitutions and better manage availability constraints.
- Pre-qualification of claims, documentation and regulatory requirements to limit late-stage feedback and better prepare multi-country launches.
- Simulation of portfolio, demand and volume / margin / service scenarios to make faster trade-offs between innovation, capacity and profitability.
- Business copilots for marketing, regulatory, procurement, supply and customer service teams, to reduce dead time between functions and accelerate operational decisions.
- Targeted diagnosis: mapping of high-value decisions where AI can reduce time, variability and cross-functional friction.
- Prioritized strategy: selection of a short portfolio of business-first use cases connected to KPIs for speed, service, margin, forecast accuracy and compliance.
- Operational deployment: integration of tools into real processes — innovation, regulatory, supply, commercial — with data governance, clear roles and impact measurement.
Measured results: faster decisions, reduced rework, improved launch quality and stronger synchronization between teams.
When AI Must Become a Driver of Speed and Precision
Trusted by leading Cosmetics companies
Contact our Cosmetics experts
Contact our Cosmetics experts